Project Grant K00CA284256
Award Date
3/1/25
Completion Date
2/28/29
Dollars Obligated
$107K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute provides $582,100 to East Carolina University to support research on the role of mitochondrial complex I deficiency in colorectal cancer (CRC) tumor growth and progression. The research aims to elucidate how accumulated mitochondrial DNA mutations that disrupt complex I activity can paradoxically support CRC tumorigenesis, despite the general requirement for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach involving DNA repair inhibition...
This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), supports research to target the evolving immunopeptidome in metastatic colorectal cancer. The $154,642 award to the Sloan-Kettering Institute for Cancer Research in New York will systematically elucidate the changing immunopeptidome - peptides presented by HLA class I molecules - from normal colon, primary tumor, and metastatic lesion patient-derived...
This National Cancer Institute (NCI) Project Grant award under CFDA 93.395 "Cancer Treatment Research" provides $627,422.00 to researchers at the Regents of the University of Michigan to develop a novel intervention against colorectal cancer associated with colibactin-producing bacteria. The project aims to optimize the surface display of an anti-toxin enzyme on commensal E. coli strains to neutralize the carcinogenic colibactin compound, thereby preventing DNA damage and reducing...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $235,620.00 to the Albert Einstein College of Medicine to support research on novel therapeutics for preventing and treating inflammation-associated colorectal cancer. The key focus of this research is on the development and evaluation of MTDIA, a targeted inhibitor of the MTAP enzyme, and related prodrug compounds. The grant funding will support studies in two novel mouse...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) will provide $2,675,483 to President and Fellows of Harvard College (Harvard Medical School) to conduct research aimed at understanding the origins and characteristics of peritoneal metastases in colorectal cancer. The 5-year project will leverage a large cohort of 103 peritoneal metastasis patients to map the seeding routes and genetic features of these metastases, as well as examine how...
This $439,367 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research to assess strategies for targeting transcriptional co-activators in colorectal cancer. The research aims to identify the protein-protein interactions required by the transcriptional co-activator PGC-1B to promote gene expression and tumor cell survival in colorectal cancers with K-RAS mutations. Key objectives include determining how...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding for research to elucidate the microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient and microsatellite-stable colorectal tumors. The $400,890 award, effective March 1, 2025 through February 28, 2028, will support the utilization of a pathomimetic colorectal cancer chip model to profile patient-specific tumor-microbiome interactions and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $158,020.00 in funding to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The key products and services to be delivered under this award include: Investigating persistence in response to PARP inhibitor treatment of BRCA1/2 mutant cancer cells to understand the mechanisms of mutagenic DNA repair,...
This Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $1,245,354 to fund research aimed at characterizing the mechanisms by which the molecular scaffold KSR1 regulates tumor initiation, drug resistance, and the epithelial-to-mesenchymal transition (EMT) in colorectal cancer. The research will utilize genetically modified colorectal cancer organoids, mouse models, and cell lines to: 1) Elucidate the KSR1-dependent pathways necessary for tumor...